Edwards Lifesciences CVP JAPAC Lippis Daniel sells 4114 shares at $79.46 on 2025-07-28.
PorAinvest
lunes, 28 de julio de 2025, 8:50 pm ET1 min de lectura
EW--
Following the sale, Lippis directly owns 22,001 shares of Edwards Lifesciences. The sale is part of a broader trend of incremental diversification observed in Lippis' trading history. Prior to this transaction, Lippis sold 330 shares on May 9, 2025, for a gross proceeds of $24,560 [2]. The filings indicate that these shares were acquired through equity compensation and are not expected to have a material impact on the company's valuation, float, or liquidity.
Analysts have characterized the filing as routine and not price-moving, noting that the aggregate value and share count are negligible and unlikely to affect the stock's price discovery or liquidity [2]. The filing highlights Lippis' ongoing efforts to diversify his holdings, rather than signaling any strategic shift in the company's operations or financial health.
References:
[1] https://www.tradingview.com/news/tradingview:1e5918624c619:0-edwards-lifesciences-corp-officer-sells-shares/
[2] https://www.stocktitan.net/sec-filings/EW/144-edwards-lifesciences-corp-sec-filing-72c2442c9997.html
Edwards Lifesciences Corporation (EW) has disclosed that Chief Value Performance (CVP) for the Japan and Asia Pacific region, Daniel J. Lippis, has sold 4,114 shares at a price of $79.46 per share on July 28, 2023.
Edwards Lifesciences Corporation (EW) has disclosed that Chief Value Performance (CVP) for the Japan and Asia Pacific region, Daniel J. Lippis, sold 4,114 shares at a price of $79.46 per share on July 28, 2023. The transaction, reported via SEC Form 4, involved a sale of 4,114 shares at a weighted average price of $79.4605, totaling $326,900 [1]. This sale represents a minor portion of the company's outstanding shares, amounting to less than 0.001% of the approximately 586.6 million shares in circulation [2].Following the sale, Lippis directly owns 22,001 shares of Edwards Lifesciences. The sale is part of a broader trend of incremental diversification observed in Lippis' trading history. Prior to this transaction, Lippis sold 330 shares on May 9, 2025, for a gross proceeds of $24,560 [2]. The filings indicate that these shares were acquired through equity compensation and are not expected to have a material impact on the company's valuation, float, or liquidity.
Analysts have characterized the filing as routine and not price-moving, noting that the aggregate value and share count are negligible and unlikely to affect the stock's price discovery or liquidity [2]. The filing highlights Lippis' ongoing efforts to diversify his holdings, rather than signaling any strategic shift in the company's operations or financial health.
References:
[1] https://www.tradingview.com/news/tradingview:1e5918624c619:0-edwards-lifesciences-corp-officer-sells-shares/
[2] https://www.stocktitan.net/sec-filings/EW/144-edwards-lifesciences-corp-sec-filing-72c2442c9997.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios